论文部分内容阅读
美国和加拿大28个医学中心参加抗帕金森氏病前瞻性临床试验。此项5年试验由国立神经病、传染病和卒中研究所(NINCDS)资助一千万美元,将确定两种药物:Deprenyl和生育酚(Tocopherol)是否能延缓或阻止帕金森氏病的发展。美国有一百万以上的人患帕金森氏病,其中多数超过60岁。每年有将近61000名青年患此病,其结局为进行性病残而造成失业。密西根大学的John Penny指出,如果证实Deprenyl
28 medical centers in the United States and Canada participated in a prospective clinical trial of anti-Parkinson’s disease. The five-year trial funded by the National Institute of Neurological, Communicable Diseases and Stroke (NINCDS) of 10 million U.S. dollars will identify two drugs, Deprenyl and Tocopherol, that delay or prevent the development of Parkinson’s disease. More than 1 million people in the United States have Parkinson’s disease, most of them over 60 years of age. Nearly 61,000 young people are suffering from the disease each year, ending with sexually transmitted diseases and causing unemployment. John Penny of the University of Michigan points out Depenyl if confirmed